Continuous lenalidomide treatment for newly diagnosed multiple myeloma

New England Journal of Medicine

Volumn 366, Issue 19, 2012, Pages 1759-1769

  Palumbo, Antonio ^a   Hajek, Roman ^f   Delforge, Michel ^h   Kropff, Martin ⁱ   Petrucci, Maria Teresa ^b   Catalano, John ^m,n   Gisslinger, Heinz ^o   Wiktor Jȩdrzejczak, Wiesław ^p   Zodelava, Mamia ^r   Weisel, Katja ^j   Cascavilla, Nicola ^c   Iosava, Genadi ^s   Cavo, Michele ^d   Kloczko, Janusz ^q   Bladé, Joan ^t   Beksac, Meral ^u   Spicka, Ivan ^g   Plesner, Torben ^v   Radke, Joergen ^k   Langer, Christian ^l   Yehuda, Dina Ben ^w   Corso, Alessandro ^e   Herbein, Lindsay ^x   Yu, Zhinuan ^x   Mei, Jay ^x   Jacques, Christian ^x   Dimopoulos, Meletios A ^y   more..

^a UNIVERSITY OF TURIN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

^h Belgian Hematologic Society   (Belgium)

ⁱ UNIVERSITY OF MÜNSTER   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^l UNIVERSITY OF ULM   (Germany)

^m FRANKSTON HOSPITAL   (Australia)

ⁿ MONASH UNIVERSITY   (Australia)

^o MEDICAL UNIVERSITY OF VIENNA   (Austria)

^p MEDICAL UNIVERSITY OF WARSAW   (Poland)

^q MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^r Clinic of Hematology and Chemotherapy Hema   (Georgia)

^s Institute for Hematology and Transfusiology   (Georgia)

^t HOSPITAL CLÍNIC   (Spain)

^u ANKARA UNIVERSITY   (Turkey)

^v LILLEBAELT HOSPITAL   (Denmark)

^w HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^x CELGENE CORPORATION   (United States)

^y UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE;

ACUTE CORONARY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART INFARCTION; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AGED; ANEMIA; ANGINA PECTORIS; APPENDICITIS; ARTICLE; BACTEREMIA; BACTERIURIA; BLEEDING; BONE PAIN; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARDIOGENIC SHOCK; CELLULITIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DIVERTICULITIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; ESCHERICHIA COLI INFECTION; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FOLLOW UP; GASTROINTESTINAL INFECTION; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MONOTHERAPY; MOUTH INFECTION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPULAR RASH; PNEUMONIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK BENEFIT ANALYSIS; SEPSIS; SEPTIC SHOCK; SINUSITIS; STREPTOCOCCUS INFECTION; SURVIVAL RATE; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTOPENIA; TOOTH INFECTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84860744403     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1112704     Document Type: Article

References (25)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
2. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from six randomized clinical trials. Blood 2011;118:1239-47.
3. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
4. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32. [Erratum, N Engl J Med 2009;361:544.] (Pubitemid 350146107)
5. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42. (Pubitemid 350146108)
6. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52.
7. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116:5838-41.
8. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
9. Attal M, Olivier P, Cances-Lauwers V, et al. Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial. Haematologica 2011;96:Suppl 1:S23. abstract.
10. McCarthy P, Owzar K, Anderson K, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104. Haematologica 2011;96:Suppl 1:S23. abstract.
11. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007; 25:4459-65. (Pubitemid 350063804)
12. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23. (Pubitemid 28435189)
13. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73. [Errata, Leukemia 2006; 20:2220, 2007;21:1134.] (Pubitemid 44264086)
14. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), v3.0 (http://ctep.cancer.gov/ protocolDevelopment/electronic- applications/docs/ctcaev3.pdf).
15. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259-66.
16. Mateos MV, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934-41.
17. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan- prednisonethalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010;28:5101-9.
18. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-18. (Pubitemid 47516593)
19. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825-31. (Pubitemid 43363369)
20. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27:3664-70.
21. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:1405-12.
22. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119:2764-7.
23. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1966: a search for common mechanisms. Br J Cancer 2001; 85:997-1005. (Pubitemid 33016003)
24. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743-8. (Pubitemid 10250478)
25. Sevilla J, Rodríguez A, Hernández- Maraver D, et al. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Ann Hematol 2002;81:11-5. (Pubitemid 36075489)